Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from the National Medical Products Administration (NMPA) for its in-licensed products JBPOS0101 and JX7002. JBPOS0101 is being assessed for focal epilepsy in adults, while JX7002 is under development for hypercholesterolemia and mixed hyperlipidemia.
JBPOS0101: A First-in-Class Drug for Focal Epilepsy
JBPOS0101 is a potential global first-in-class drug that reduces neuronal firing by binding to metabotropic glutamate receptors. These receptors, part of the G protein-coupled receptor family, are involved in learning, memory, emotion, and pain perception, making them a potential target for depression and other central nervous system diseases. Jingxin obtained development, manufacturing, and commercialization rights to JBPOS0101 in a USD 40 million deal with South Korea’s Bio-Pharm Solutions Co. Ltd in August 2021, securing rights in mainland China, Hong Kong, and Macau.
JX7002: A Biologic Targeting PCSK9
JX7002 is a Category 1 biologic product targeting PCSK9, currently under development for hypercholesterolemia and mixed hyperlipidemia. The drug has completed preclinical pharmacy and nonclinical studies. Jingxin partnered with UK-based Kymab for JX7002 in February 2017, with Kymab responsible for determining the development candidate sequence and Jingxin leading the clinical studies.-Fineline Info & Tech
